Table 1.

List of approved ATP-competitive inhibitors and respective indications

First generation
Imatinib	First-line and second/subsequent-linea, all disease phases
Second generation
Dasatinib	First-line and second/subsequent-line, all disease phases
Nilotinib	First-line and second/subsequent-line, CP and AP only
Bosutinib	Third-line or when imatinib, dasatinib or nilotinib are not considered appropriate, all disease phases
Third generation
Ponatinib	Second/subsequent-line if T315I+ or when no other TKI is considered appropriate, all disease phases

^abeing the weaker of all, imatinib is rarely considered as second/subsequent line option especially in case of resistance